RUNNING HEAD: Refractory Inflammatory Arthritis revised definition and model

MANUSCRIPT TITLE: Refractory Inflammatory Arthritis definition and model generated through patient and multi-disciplinary professional modified Delphi process

Authors: Hema Chaplin[1] MSc, Ailsa Bosworth[2] MBE, Carol Simpson[3], Kate Wilkins[3], Jessica Meehan[1] MSc, Elena Nikiphorou[3] MBBS, MRCP, MD(Res), Rona Moss-Morris[1] PhD, *Heidi Lempp[3] PhD, *Sam Norton[1,3] PhD. *Joint Last Author

Affiliations: [1]Health Psychology Section, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK. [2]National Rheumatoid Arthritis Society; [3] Centre for Rheumatic Diseases, King's College London, London, UK.

Corresponding Author: Hema Chaplin, hema.chaplin@kcl.ac.uk, (+44)20 7188 0192, Health Psychology Section, Institute of Psychiatry, Psychology & Neuroscience, King's College London, 5th Floor Bermondsey Wing, Guy's Hospital, London Bridge, London SE1 9RT.ORCID ID: 0000-0002-9402-9669

Word Count: 4,501/5,000 plus 250/250 Abstract

References: 49/50

Funding: This paper represents independent research funded by the National Institute for Health Research (NIHR) Maudsley Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London, in the form of a PhD Studentship (IS-BRC-1215-20018) for the first author (HC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.

Data availability: The data generated that support the findings of this study are available from the corresponding author, HC, upon reasonable request.

CRediT Author Statement: Hema Chaplin: Conceptualization, Methodology, Formal analysis, Investigation, Writing – Original Draft, Visualization, Project Administration, Funding Acquisition. **Ailsa Bosworth**: Writing - Review & Editing, Project Administration (Nominal Group), Supervision (Patient Representative). **Carol Simpson:** Writing - Review & Editing, Supervision (Patient Representative). **Kate Wilkins:** Writing - Review & Editing, Supervision (Patient Representative). **Jessica Meehan:** Formal analysis, Writing - Review & Editing. **Elena Nikiphorou:** Writing - Review & Editing, Supervision (Clinical). **Rona Moss-Morris:** Methodology, Writing - Review & Editing, Visualization, Supervision (Academic). **Heidi Lempp:** Conceptualization, Methodology, Formal analysis, Writing – Original Draft, Writing - Review & Editing, Visualization, Supervision (Academic), Funding Acquisition. **Sam Norton:** Conceptualization, Methodology, Formal analysis, Writing – Original Draft, Writing - Review & Editing, Visualization, Supervision (Academic), Funding Acquisition.

Ethical Approval: Full NHS ethical approval granted in July 2018 by London – Hampstead Research Ethics Committee (18/LO/1171).

Conflict of Interests: None

Table and Figure Legends in Manuscript (6)

Figure 1: Study Overview

Table 1: Characteristics of Delphi Voters (n=106)

Table 2: Revised consensus definition of Refractory Inflammatory Arthritis

Table 3: Assessments mapped onto Refractory Inflammatory Arthritis definition

Figure 2: Round One Domains and Round Two Components Inclusion

Figure 3: Proposed Conceptual Model of Refractory Inflammatory Arthritis

Supplementary Material Legends (9)

Supplementary Figure S1: Key components of Refractory Disease and Persistent Symptoms identified by Patients and Rheumatologists during Qualitative Interviews.

Supplementary Data S2: Lists of Components and Domains presented during a) Nominal Group, b) Round One Online Voting, and c) Round Two Online Voting

Supplementary Data S3: Example of Delphi Voting Questions (Round One Online)

Supplementary Figure S4: Analysis of Participants across Delphi Rounds

Supplementary Data S5: Options for Name preference voting with Proportions and 95% Confidence Intervals

Supplementary Figure S6: Overview of Definition Development and Refinement

Supplementary Figure S7: Round One Rankings of Domains by Role Group

Supplementary Data S8: Refractory Inflammatory Arthritis Definition Components Statistics

Supplementary Figure S9: Example selection of components for inclusion or exclusion from included domain

ABSTRACT

Objective: Various definitions have been proposed for Refractory Disease in people with Rheumatoid Arthritis (RA); however, none were generated for Polyarticular Juvenile Idiopathic Arthritis (PolyJIA) or involving adult and paediatric multidisciplinary healthcare professionals and patients. The study aim is to redefine Refractory Disease, using Delphi methodology to include these cohorts.

Methods: Three rounds of surveys with experts (one nominal group and two online) to achieve consensus using a predetermined cut-off were conducted voting on: a) name, b) treatment and inflammation, c) symptoms and impact domains, and d) rating of individual components within domains.

Results: Votes were collected across three rounds from Patients, Researchers and nine multi-disciplinary healthcare professional groups (n=106). Refractory Inflammatory Arthritis was the most popular name. Regarding treatment and inflammation, these were voted to be kept broad rather than specifying numbers/cut-offs. From 10 domains identified to capture symptoms and disease impact, six domains reached consensus for inclusion: 1) Disease Activity, 2) Joint Involvement, 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) Disease-Modifying Anti-Rheumatic Drug Experiences. Within these domains, 18 components, from an initial pool (n=73), were identified as related and important to capture multi-faceted presentation of Refractory Inflammatory Arthritis, specifically in RA and PolyJIA.

Conclusion: Refractory Inflammatory Arthritis has been found to be broader than not achieving low disease activity, with wider biopsychosocial components and factors incorporating Persistent Inflammation or Symptoms identified as important when

defining this concept. This definition needs further refinement and validation to assess utility to identify patients with unmet needs.

Keywords: Multi-disciplinary Healthcare-Professionals, Refractory Disease, Rheumatoid Arthritis, Persistent Symptoms, Polyarticular JIA.

What is already known on this topic

- In recent years within Rheumatology, parallel bodies of work have reached similar conclusions regarding the broadening of the Refractory or the wider Difficult-to-Treat concept.

What this study adds

- In this paper, we provide a different angle to define, measure, and conceptualise Refractory Inflammatory Arthritis (RIA), using health psychology theory across PolyJIA and RA with the input of patients, rheumatologists, and multi-disciplinary HCPs.
- We support and extend recent definitions of refractory rheumatoid arthritis (1, 2) by detailing a three-part definition identified as important to both patients and multi-disciplinary healthcare professionals that can also be applied to Polyarticular Juvenile Idiopathic Arthritis: 1) Treatment, 2) Inflammation, and 3) Symptoms and Impact with 18 specific components within 6 domains.
- We have applied a biopsychosocial formulation model for Refractory Inflammatory Arthritis covering perpetuating and protective factors to guide management strategies and present wider contextual factors involved in the experience of Refractory Inflammatory Arthritis.

How this study might affect research, practice or policy

- The development of the Refractory Inflammatory Arthritis definition presented here included consideration of content and discriminant validity indicators to provide a clinical and research tool to appropriately classify and measure Refractory Inflammatory Arthritis with alignment to routinely used measures (3).

Introduction

Refractory Disease (RD) in people with rheumatoid arthritis (RA) refers to the persistence of disease activity and symptoms despite treatment with multiple drugs with different mechanisms of action (4), by not achieving low disease activity target after resistance to two or more biologics (1, 5-7). Previous definitions of RD have focused on biological underpinnings based on rheumatologist experience alone (if definition generation stated) (4), however, wider psychosocial components need to be incorporated from a multi-disciplinary perspective (8). Therapeutic strategies following a treat-to-target regimen are successful in reducing inflammatory markers, however patient-reported outcomes have not similarly improved (3, 9).

There is evidence that patients' prefer holistic approaches adopting patient-centred care (10) to avoid the misattribution that symptomatology is solely due to inflammation. This current project, along with others (1, 7), stems from a Versus Arthritis workshop in 2015 on the topic of RD that highlighted the need for a broader definition, incorporating the patient perspective (11). A key knowledge gap identified was differences in patients and clinicians' definitions of RD. The biopsychosocial model of RD is poorly understood and refining the concept could identify novel approaches to adopt a broader perspective to treatment and care.

Although current RD research focuses on Rheumatoid Arthritis (RA), there is clear justification for incorporating Polyarticular Juvenile Idiopathic Arthritis (PolyJIA), particularly for those now in adulthood, who despite presenting a RD course are commonly excluded from such research therefore outcomes and impact of disease and treatment are not fully understood and under recognised (4, 12). Since JIA, and in particular the Polyarticular subset, are not benign and self-limiting to childhood (13), it is important and clinically useful to utilise a common language and approach to

classify and treat these patients similarly to other rheumatic diseases seen in adult rheumatology care (14).

Absence of a systematic approach to identify or evaluate RD means the true impact and underlying mechanisms remain largely unknown (7). The growing number of publications on this topic (4) and European Alliance of Associations for Rheumatology (EULAR) Task Force on the wider concept of Difficult-to-Treat RA (1), highlights the need to identify, consolidate and implement additional components of RD. This could assist identifying patients who may benefit from pharmacological versus non-pharmacological interventions, and address additional strategies, such as coping and self-management.

The aim was to explore and refine the definition of Refractory Disease (RD) considering the perspectives of healthcare professionals (HCPs) and patients, explore its meaning and implications, and identify uncertainties about the terminology and components. The primary objective was to reach a revised consensus definition of RD in RA and PolyJIA from across multi-disciplinary HCPs and patients' perspectives.

Materials and Methods

Design

The current study was designed and set up following the Versus Arthritis workshop (11), comprising of a PhD studentship initiated in 2017. The study involved two phases: 1) Component Development and 2) Delphi Voting (Figure 1). In phase 1, a pool of components was developed based on a multimodal evidence synthesis. We use the term components to refer to specific facets that operationalise RD (e.g. synovitis, joint pain). In phase 2, a consensus definition of RD was developed using a Delphi approach, by surveying panels of experts to achieve a group agreement or

convergence of opinion (15). Components not included in the consensus definition were retained in a broader conceptual model. As this is an observational study, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement guidelines (16) have been adhered to, where appropriate, and checklist for cohort studies included.

Component Development

Components of RD were identified from: 1) qualitative interviews and focus groups with patients and HCPs (17), 2) systematic review of studies of RD in RA/PolyJIA (4), and 3) review and application of biopsychosocial theories regarding chronic illness and persistent symptoms. Firstly, inductive thematic analysis of 25 patient and 32 HCP interviews identified 17 components for common experiences of RD and persistent symptoms, whilst an additional seven were patient-specific (including JIA-specific) and four professional-specific (17) (see Suppl1). Secondly, a systematic review of existing definitions (4) identified three key elements of RD: 1) treatment, 2) presence or absence of inflammation and 3) symptoms and impact. These elements were used to group the components and a three-part definition was explored. Due to the large number of components identified, and to account for similarities between components, these were grouped thematically into higher level domains (e.g. disease activity, pain).

From the interviews and systematic review, it became clear that some factors (e.g. reduced mobility) are related to defining RD, whilst others (e.g. social support) are more relevant to describing poor prognostic, perpetuating or protective elements related to the experience of RD. These factors can guide treatment strategies in line with a biopsychosocial formulation (18-20). This is an integrative process that enables

consideration of the complex, interacting factors implicated in development of a patient's presenting problems to translate the diagnosis into specific, individualised interventions. This formulation has not previously been applied to RD and could help holistically define and explain RD drawing from theoretical models such as Adjustment to Chronic Illness and Illness Perception Models (21, 22) by aligning identified concepts to established theories and utilising their terminology and descriptions. These theoretical models outline the individual behavioural, emotional and cognitive factors involved in adjustment and adaptation to chronic illness related to the return to equilibrium following critical illness events/stressors.

Findings from these three areas of research were combined during phase 1 to develop an initial 72 components across 12 domains (see Suppl2) for the Delphi phase (23), by mapping these concepts onto currently used measures within Rheumatology (24) such as Musculoskeletal Health Questionnaire (MSK-HQ) (25) and Health Assessment Questionnaire (HAQ) (26) to increase utility and validity. The specific wording of the components was agreed by the wider study team (HC, SN, HL, CS, KW and EN).

Delphi Voting

The Delphi method allows synthesis of the best available information, an anonymous and iterative process of consensus and validation between key stakeholders/end-users, with feedback thereby increasing ownership and engagement (27). Here we used a modified Delphi process through an initial face-to-face nominal/expert group (September 2019), followed by two rounds of Delphi surveys online (March-May 2020) (15, 23, 28-30) to vote on preferred terminology and variables that define RD. Specifically, we sought consensus on (i) preferred name, (ii)

domains to retain in the definition, and (iii) components to retain within each domain. The process was managed by a non-voting co-ordinator (HC).

a) Participants and Sample size

A purposive sampling strategy (31) was employed to identify potential Delphi participants who had experience of RD and/or persistent symptoms in RA/JIA. Three independent inclusion criteria determined who was invited (31): (1) Patients with RA/PolyJIA or HCPs within Rheumatology, (2) involvement with RA/JIA patient organisations or (3) recognized academic career in RD or Persistent symptoms in RA/JIA. Participants were contacted via e-mail and invited to participate anonymously online via Qualtrics software (Qualtrics 2020, Provo, UT), to take part in all online rounds of voting, regardless of whether they had participated in the previous round. This was to ensure a wide representation and allow recruitment to target during COVID-19 since many academics and HCPs were redeployed to frontline NHS services during this time (March and May 2020). Written informed consent was obtained prior to participation in each round.

There is currently no formal sample size calculation in Delphi processes (15). A pragmatic approach was adopted in line with previous literature (28-30). The absolute minimum sample size agreed was 12 per round, with at least three members per participant group (Rheumatologists, other HCPs, Patients, and Researchers). A target sample size of at least 40 was set for the online surveys based on estimated 95% confidence intervals (CIs) providing sufficient precision to discriminate between domains rated for inclusion/exclusion from the consensus definition. A total of 89 participants were invited to allow for non-response and attrition.

b) Data Collection and Analysis

Four different stages of analysis were conducted: 1) Name ranking, 2) Treatment/Inflammation cut-off inclusion, 3) Symptoms/ Impact domain inclusion, and 4) Component importance rating. Firstly, proportions and 95% CIs were calculated to determine the name preference voting. Participants indicated their top three name choices in each round with the choice receiving majority vote in the final round proposed as the final definition name. Secondly, for the treatment and inflammation questions, there was a need to achieve consensus on whether the definition needs to specify distinct cut-offs or include a broader statement (see Suppl3). Options receiving most responses in the first round were taken forward to the next round. Thirdly, for each domain participants were asked to rate whether the domain needed inclusion on a nine point Likert scale (1='Definitely Not Include' to 9='Definitely Include') (15). In line with previous literature (28-30), a priori level of agreement was required (≥70% rating domains 7-9 for inclusion and 1-3 for exclusion). Mean and 95% CIs were also estimated to allow consideration of the certainty of domain inclusion or exclusion.

Finally, for each component, participants were asked to rate how related the component is to assess a) Refractory Arthritis, and b) Disease flare (-3='Highly Unrelated' to 3='Highly Related'), and to provide comments to clarify component meaning (28) (See Suppl3). Inclusion of components in the consensus definition was based on: a) high mean related total scores for Refractory Arthritis, and b) mean difference and effect sizes between ratings for Refractory Arthritis and Disease Flare. This second criterion allowed discriminant validity to be established to ensure selected components appropriately differentiated between these two constructs. Scores within participant groups were also considered to identify differences across groups and ensure that components rated as important by one group, particularly patients and rheumatologists, were not excluded.

Several exploratory subgroup analyses were undertaken to assess differences across the four different role groups (Patients, Rheumatologists, Other HCPs and Researchers), in terms of representation across the different rounds of voting in both those who started and completed all voting, and in ranking and scoring of the symptoms and impact domains for inclusion. To assess whether there were any differences across the different rounds of voting regarding the sociodemographic characteristics such as years of rheumatology experience and adult versus paediatric trained, one-way ANOVAs were conducted for continuous variables and Fishers exact tests for categorical variables due to low numbers per category. To assess differences across the clinical role groups (Rheumatologists, Patients and Other Healthcare Professionals) in voting on domains for inclusion, simple linear regressions for each domain were conducted with additional tests and contrasts to determine significant variability.

The minimum response for each domain was set at ≥75% (30) and only whole domains could be missing rather than components within domains due to the software used for data collection, further analysis such as mixed-effect models was not required to adjust for missing data. Additional analysis of the related ratings to generate Item-level Content Validity Indexes (I-CVI) (32) was conducted to ensure the final definition is composed of an appropriate components to adequately represent the construct of interest whilst also considering inter-rater agreement to reflect consensus. The final chosen components were then again mapped onto to routinely used measures identified from literature searching (33, 34).

Patient and Public Involvement

Patients were involved in the design, conduct, reporting, and dissemination of this research, in which AB, CS and KW have been integral at all stages as Patient

Research Partners. Numerous others were involved in the design of this project which evolved through various stages of involvement with people with RA and PolyJIA. Both diagnoses were included because early patient and public involvement work revealed that RD is a problem across both age and disease groups.

Results

Sample characteristics

Across the three rounds,106 votes were cast in this Delphi study as seen in Table 1. Due to anonymity, the total number of unique participants or number of rounds each participant voted in cannot be determined. There were no differences in participant characteristics (e.g. Rheumatology experience or diversity of roles) between each round for those that completed, nor between those who dropped out (n=3 each online round) (see Suppl4). In Round One, duplicate data for two responses (e.g. started survey on one device then continued on another) was removed, otherwise attrition occurred such that domain completion rates were between 90-100%, therefore meeting the pre-determined minimum response rate. In Round Two, the attrition occurred after the name ranking questions, with otherwise complete data.

Name Preference Voting

During the nominal group workshop (one missing voter due to late arrival), ten terms were voted on for the name of the definition, of which RD, Persistent Disease and Treatment Resistant were the most popular (see Suppl5). Moreover, participants suggested that the terminology should include Part A and Part B elements to form different name iterations to be voted on subsequently, with the following additions: ‘Ongoing’, ‘Inflammatory Arthritis’, ‘Syndrome’, ‘Inflammation’ and ‘Symptoms’.

Consequently, the top three preferences from Round One online voting were combined to create nine names involving all combinations of the label (e.g. refractory, resistant) and target (e.g. inflammatory arthritis, disease), which participants were asked to again select their top three in Round Two (see Suppl5). Refractory Inflammatory Arthritis received the majority vote (25% of votes), followed by Persistent Inflammatory Arthritis (19% of votes). There was slight disparity in the top preference between Patients and the other three groups as Persistent Inflammatory Arthritis received 21.6% of the votes by Patients whilst both RIA and RD received 15%.

Definition of Refractory Inflammatory Arthritis

Based on the Delphi process, a consensus definition for RIA is proposed in Table 2. This three-part definition covers the core elements identified in phase 1: 1) treatment, 2) inflammation presence (Persistent Inflammation) or absence (Persistent Symptoms) and 3) symptoms and impact, which comprises 18 components across 6 domains to capture the presentation and experience of RIA. To identify a patient as having RIA, at least one component from each part 1-3 need to be met, and suggestions for assessment for each component are proposed in Table 3. These are based on commonly used measures in paediatric and adult rheumatology clinical cohorts and registers (33, 34), with some suggested cut-offs or scoring direction on continuous measures.

An overview of the phases of definition development including refinements and voting results during Delphi rounds are presented in Suppl6. Nominal group attendees agreed all 12 domains (85-100%) to be included in the next stage of voting. All domains were voted as related to RD, with Pain, DMARD Experiences, Joint Activity and Co-morbidities rated the most highly, whilst Poor Quality Sleep, Steroid Use and

Dependency and Social Functioning and Quality of Life were rated the lowest. Discussion included the addition of Healthcare Utilisation (eight components) to the Steroids domain, with refinements/additions to eight other components e.g. sex, benefits, variability, assessment of feet and removal of one component ("unable to relax easily"). They also stated the importance of investigating other undiagnosed underlying reasons for these symptoms in case these treatable causes are driving suspected RD e.g. thyroid issues causing fatigue. Further discussions with the study team and Health Psychology Group at KCL took the final total count of components identified for voting to be 73 across 10 domains as the three Functioning and Quality of Life Domains were condensed into one domain (see Suppl2).

In Round One online voting, for Parts One and Two regarding Treatment and Inflammation factors, the consensus was for these to be kept broad (65-70%) as originally proposed rather than specifying fixed cut-offs (Tables 2 and 3). As seen in Figure 2, seven domains in Round One met consensus criteria for inclusion (≥70% rating the domain between 7-9 for inclusion on the 1-9 scale) for Part 3 Symptoms and Impact. Of these, three were clearly above this inclusion threshold, whilst the remaining four indicate uncertainty as to the generalisability of inference. The remaining three domains did not reach agreement whether to include or exclude, and when converted into rankings were consistently the lowest across the different role groups (see Suppl7). Rheumatologists and Other Healthcare Professionals ranked Joint Activity highest, then Stiffness and Disease Activity in their top three. Whereas Patients ranked Disease Activity and Fatigue jointly highest with Pain third as their top three, therefore more symptom focussed. Researchers ranked Disease Activity highest then Pain and Functioning and Quality of Life as joint second in their top three.

Regression analyses revealed no differences in mean include scores across the training specialties (Adult vs Paediatric vs Both), however there were some subtleties in the domains reaching criteria for inclusion. Analyses highlighted the different priorities and considerations for HCPs with paediatric versus adult patients. For Paediatric professionals, Fatigue (66.67%) and DMARD experiences (33.33%) did not reach inclusion criteria, with Pain (66.67%) and Functioning and Quality of Life (66.67%) also falling short for those trained in Both. There was greater variability in responses for the group that had received both Adult and Paediatric training, who were heterogenous population that encompassed a mixture of Researchers, Rheumatologists, a Physiotherapist and a GP.

From Round One voting, 30 components from the seven included domains were retained based on mean related scores and the difference with flare, and I-CVI scores. The core study team (HC, SN, HL) then discussed and prioritised those with higher mean related score, followed by those with medium-to-large difference whilst considering the I-CVI and any free text comments regarding modification and clarification (see Suppl8 & Suppl9). This resulted in final data driven selection of 16 components, through combining two domains (Joint Activity and Stiffness into Joint Involvement) and combining some components (e.g. Pain during the day and Pain during the night combined into Pain during day and/or night).

Thirteen components, not achieving consensus in round one, were taken forward to Round Two (see Suppl2): nine components from Sleep, Co-morbidities and Wider Involvement Outside of Joints and Healthcare/Medication Utilisation and exploration of four exclusion criteria from components voted in Round One as highly unrelated. From Round Two, only two components out of the 13 voted upon reached the required criteria for inclusion (see Figure 2), taking the total number of components

achieving consensus for inclusion to 18. The core research team decided not to hold a third round of online voting as only three components had not achieved consensus for inclusion or exclusion. Given each included domain consisted of at least two components, these three components were excluded from the definition.

Refractory Inflammatory Arthritis (RIA) Conceptual Model

A wider conceptual model was generated by the core research team to allow for consideration of the relationship between the domains and components excluded from the consensus definition and RIA, based on the Phase 1 development work (4, 17). The concepts and examples given here are based on findings from the systematic review highlighting the role of other contributing factors such as Serology and fixed disease factors such as disease duration (4) and qualitative work on patients' and HCP' experiences of RIA (17) (see Suppl1) such as social support and independence which included elements such as adjustment, resilience and illness/treatment beliefs which align with general theories of perceptions and adjustment to long-term illness. This followed a Biopsychosocial Formulation (18, 19) (see Figure 3), with the Definition of RIA with Persistent Symptoms or Inflammation at the core, surrounded by Predisposing, Poor Prognostic, Perpetuating and Protective factors.

Some of the Precipitating factors are the same to RA/PolyJIA generally, whilst Poor Prognostic factors suggest some mechanisms identified for those that then lead to have a more refractory course, which therefore cannot be modified. However, building on these symptoms and impact are the Protective and Perpetuation factors that describe some of the biopsychosocial mechanisms underpinning why some patients may experience negative and worsening impact of RIA (Perpetuating) on their daily lives whilst others appear to manage and live with reduced impact (Protective),

despite experiencing RIA with Persistent Symptoms or Inflammation. The allocation of factors is individual and based on the Impact Triad (35), which includes the patient's perceived severity, importance and ability to self-manage/cope with the factor or symptom to determine patient priorities from the level of perceived impact. The Protective and Perpetuating factors can be modified and targeted to reduce disease impact and improve quality of life. This conceptual model allows for the identification of potential risk factors and interventional targets that Rheumatologists and other HCPs can consider as part of the shared decision-making process of deciding which treatments may be most appropriate for patient.

Discussion

This study presents the development of a consensus definition for Refractory Inflammatory Arthritis (RIA) with Persistent Symptoms or Inflammation across multi-disciplinary HCPs and patients, in line with the study aim and objective. This three-part definition covers core elements of treatment, presence or absence of inflammation, and symptoms and impact, including: 1) Disease Activity, 2) Joint Involvement, 3) Pain, 4) Fatigue, 5) Functioning and Quality of Life, and 6) DMARD Experiences. This captures the multi-faceted presentation and experience of RIA in RA and PolyJIA populations covering biological and psychological symptoms. This work replicates and supports the growing body of evidence to understand and refine the concept of Refractory Disease (RD), notably the EULAR Difficult-to-Treat Task Force and others (1, 2, 6, 7, 36, 37). It is worth noting that the current study was designed and set up in 2017, as part of a Health Psychology PhD programme of research before publication of the EULAR Difficult-to-Treat Task Force work. These parallel bodies of work have reached similar conclusions that a broader definition

needs to include treatment, symptoms (including inflammation) and impact as part of the RIA concept, however these have been more generally stated (1, 2).

Here we suggest an extension to the general criterion recently proposed by detailing a three-part definition identified as important to both patients and multi-disciplinary HCPs with 18 specific components within 6 domains. Additionally, our definition has been derived through a different evidence synthesis approach, e.g. systematic review, qualitative interviews, application of biopsychosocial theory and Delphi consensus voting. Another distinguishing feature of this study is participation of patients, multi-disciplinary professionals from nine relevant specialties and researchers across both adult and paediatric services to include PolyJIA within this refractory concept, which has not previously occurred in definition development (4). Another feature was the selection of the name for the definition, which fits with the common use of the term Refractory in the literature (4), and the distinction with Difficult-To-Treat Disease (2).

For Paediatric professionals, Fatigue and DMARD experiences did not reach inclusion criteria. However, it is important to bear in mind the lower sample sizes for the Paediatric and Both groups compared to the Adult sample, therefore no firm conclusions can be drawn to suggest these domains and their components would need to be removed for a paediatric specific definition. Given there were no significant differences in the domain means, it seems that the proposed definition based on the whole group scores may be appropriate for use in the paediatric PolyJIA population as well, and requires further exploration. This study has shown that it is feasible to include both adult and paediatric professionals and patients. Given the relative rarity of JIA and those specialising in paediatric and adolescent rheumatology, the use of a transdiagnostic approach in future research can be advantageous.

Unlike previous definitions (4), the development of the new RIA definition presented in this paper included consideration of content and discriminant validity indicators (I-CVI and mean difference with flare) and therefore provides a tool to appropriately identify and measure RIA, alongside a conceptual model of related factors. This RIA definition could serve as a clinical or research checklist with the components aligned to routinely used measures (33, 34), as listed in Table 3 to enable identification of aspects requiring further support e.g. low HAQ indicating issues with functioning and quality of life (Domain 5) could prompt a referral to Occupational and Physiotherapies (3).

Within the RIA model presented here, Protective and Perpetuating Factors suggest some of the underlying biopsychosocial mechanisms that may explain why some patients experience negative and worsening impact of RIA in their lives (Perpetuating) whilst others have minimal or less impact despite experiencing RIA (Protective). By identifying the specific Protective and Perpetuating factors deemed to have an impact through biopsychosocial formulation for each patient (18, 19, 35), it may be possible to address these wider clinical and sociodemographic factors that contribute to non-response to treatment, which is important to identify those requiring additional non-pharmacological support from a multi-disciplinary team (3, 8, 20, 37). This fits with subsequent EULAR work which identified multiple contributing factors, a high burden of disease and the heterogeneity of Difficult-To-Treat RA (38), suggesting that these factors should be identified in daily practice in order to tailor therapeutic strategies further to the individual patient with the RIA model providing such a framework.

Future work could explore the application and validity of the RIA definition in other Rheumatic Musculoskeletal Diseases, both adult and juvenile variations.

Appropriate adult and paediatric measures have been proposed to measure RIA (24), which require further validation to assess practicality and feasibility, and could initiate development of classification criteria. Several options have been put forward as examples and other appropriate measures, such as other measures for Fatigue and Pain Interference (24), can also be used to enable flexibility and usability with multiple and various multi-disciplinary HCPs consultations as part of a RIA Clinic.

Several limitations and potential bias within the current study should be discussed. It would have been useful to have a patient and clinician included in the core study team discussions during the delphi voting iterations following nominal group discussions however this process was data driven with little subjective decision making made by the researchers involved. Since most domains met pre-defined inclusion criteria in the first round, the process was less iterative than previous Delphi studies (29, 30), without continuous re-voting on the same components and due to anonymity the team was unable to provide individualised feedback to voters. This may be a consequence of online data collection, rather than a face-to-face meeting with further deliberation. However, the completion of an online questionnaire enabled a larger number of participants to take part, specifically during the first COVID-19 wave. There was a predominant bias towards participants from the UK followed by Europe and caution is required for applicability of this definition in other countries. This project determined a preliminary definition of RIA, requiring further validation to explore staging within the definition to account for severity and differences between conditions and countries. The refinement could be achieved through assessment of retrospective cohorts and datasets from the UK, followed by different global cohorts.

Conclusion

Within Rheumatology, parallel bodies of work have reached similar conclusions regarding the broadening of the Refractory or the wider Difficult-to-Treat concept. The authors provide a different angle to define, measure, and conceptualise Refractory Inflammatory Arthritis (RIA), using health psychology theory across PolyJIA and RA with the input of patients, rheumatologists, and multi-disciplinary HCPs. The multi-factorial definition and model proposed can help to identify patients experiencing RIA where inflammation and/or symptoms persist despite treatment and allow for the consideration of wider contextual factors that may not be targeted by pharmacological treatments.

Acknowledgements: Thank you to all the patients and healthcare professionals that took part in the Delphi voting and to the Refractory Delphi Nominal Group which comprised of Ailsa Bosworth, Sam Norton, Heidi Lempp, Katie Bechman, Wendy Olsder, Di Skingle, Flora McErlane, Louise Parker, Elena Nikiphorou, Lianne Kearsley-Fleet, Simon Black, Adam Young, and Kevin Davies. Finally, thank to you to Nora Ng, James Galloway, Ian Scott, Debajit Sen, and Rachel Tattersall for support and help recruiting to the qualitative study.

References

1. Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases. 2020;80:31-5.
2. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nature Reviews Rheumatology. 2021;17:17-33.

3. Schoemaker CG, de Wit MPT. Treat-to-Target From the Patient Perspective Is Bowling for a Perfect Strike. Arthritis & Rheumatology. 2021;73(1):9-11.
4. Chaplin H, Carpenter L, Raz A, Nikiphorou E, Lempp H, Norton S. Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review. Rheumatology. 2021;60(8):3540-52.
5. Polido-Pereira J, Vieira-Sousa E, Fonseca JE. Rheumatoid arthritis: what is refractory disease and how to manage it? Autoimmun Rev. 2011;10(11):707-13.
6. Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77(10):1405-12.
7. Buch MH. Defining refractory rheumatoid arthritis. Annals of the Rheumatic Diseases. 2018;77(7):966-9.
8. Zembrzuska H, Kumar B. Further Considerations of the Need for Integrated Mental Health Treatment in Rheumatoid Arthritis Patients: Comment on the Review by Matcham et al. Arthritis & Rheumatology. 2019;71(6):1024-5.
9. Carpenter L, Nikiphorou E, Kiely PDW, Walsh DA, Young A, Norton S. Secular changes in the progression of clinical markers and patient-reported outcomes in early rheumatoid arthritis. Rheumatology. 2020;59(9):2381-91.
10. Radner H, Yoshida K, Frits M, Iannaccone C, Shadick NA, Weinblatt M, et al. The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology. 2015;54(11):2076-84.
11. Young A. Minutes from ARUK clinical study group refractory disease workshop: Prevalence of refractory disease in the UK. 2015.
12. Barbara Ansell National Network for Adolescent and young adult Rheumatology (BANNAR). BANNAR statement of understanding of current clinical practice for biologic and biosimilar use in JIA in the UK. 2017.
13. Armon K. Outcomes for juvenile idiopathic arthritis. Paediatrics and Child Health. 2018;28(2):64-72.
14. Fernandes S, Gomes JAM, Gomes SM, Martins F. Juvenile idiopathic arthritis: the transition to adulthood. Pediatric rheumatology online journal. 2014;12(Suppl 1):P193-P.
15. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. International journal of clinical pharmacy. 2016;38(3):655-62.
16. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453-7.
17. Chaplin H, Verhey I, Ng N, Galloway J, Scott I, Sen D, et al. AB0372 Exploring Refractory Disease & Persistent Symptoms in RA/PolyJIA despite bDMARDS: Patient & Professional Experiences. Annals of the Rheumatic Diseases. 2019;78(Suppl 2):1646-.
18. Jellinek MS, McDermott JF. Formulation: Putting the Diagnosis Into a Therapeutic Context and Treatment Plan. Journal of the American Academy of Child & Adolescent Psychiatry. 2004;43(7):913-6.
19. Winters NC, Hanson G, Stoyanova V. The case formulation in child and adolescent psychiatry. Child and adolescent psychiatric clinics of North America. 2007;16(1):111-32, ix.

20. Carroll S, Moon Z, Hudson J, Hulme K, Moss-Morris R. An Evidence-Based Theory of Psychological Adjustment to Long-Term Physical Health Conditions: Applications in Clinical Practice. Psychosomatic Medicine. 2022;84(5):547-59.
21. Leventhal H, Meyer U, Nerenz U. The common sense model of illness danger. In: Rachman S, editor. Medical psychology. 2. New York: Pergamon; 1980. p. 7–30.
22. Moss-Morris R. Adjusting to chronic illness: time for a unified theory. Br J Health Psychol. 2013;18(4):681-6.
23. Fernández-Ávila DG, Rojas MX, Rosselli D. The Delphi method in rheumatology research: are we doing it right? Revista Colombiana de Reumatología (English Edition). 2020;27(3):177-89.
24. Hannan M, Katz PPE. Patient Outcomes in Rheumatology, 2020 A Review of Measures [Special Issue]. Arthritis Care & Research. 2020;72(S10):1-749.
25. Hill JC, Kang S, Benedetto E, Myers H, Blackburn S, Smith S, et al. Development and initial cohort validation of the Arthritis Research UK Musculoskeletal Health Questionnaire (MSK-HQ) for use across musculoskeletal care pathways. BMJ Open. 2016;6(8).
26. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and rheumatism. 1980;23(2):137-45.
27. Halcomb E, Davidson P, Hardaker L. Using the consensus development conference method in healthcare research. Nurse researcher. 2008;16(1):56-71.
28. Maher TM, Whyte MK, Hoyles RK, Parfrey H, Ochiai Y, Mathieson N, et al. Development of a Consensus Statement for the Definition, Diagnosis, and Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis Using the Delphi Technique. Adv Ther. 2015;32(10):929-43.
29. Weerdesteijn KHN, Schaafsma FG, van der Beek AJ, Anema JR. Limitations to Work-Related Functioning of People with Persistent "Medically Unexplained" Physical Symptoms: A Modified Delphi Study Among Physicians. J Occup Rehabil. 2017;27(3):434-44.
30. McCann LJ, Pilkington CA, Huber AM, Ravelli A, Appelbe D, Kirkham JJ, et al. Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. Annals of the Rheumatic Diseases. 2018;77(2):241-50.
31. Diaz-Ledezma C, Higuera CA, Parvizi J. Success After Treatment of Periprosthetic Joint Infection: A Delphi-based International Multidisciplinary Consensus. Clinical Orthopaedics and Related Research®. 2013;471(7):2374-82.
32. Polit DF, Beck CT, Owen SV. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health. 2007;30(4):459-67.
33. Radner H, Dixon W, Hyrich K, Askling J. Consistency and Utility of Data Items Across European Rheumatoid Arthritis Clinical Cohorts and Registers. Arthritis Care & Research. 2015;67(9):1219-29.
34. Beukelman T, Anink J, Berntson L, Duffy C, Ellis JA, Glerup M, et al. A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. Pediatric Rheumatology. 2017;15(1):31.
35. Sanderson TC, Hewlett SE, Flurey C, Dures E, Richards P, Kirwan JR. The Impact Triad (Severity, Importance, Self-management) as a Method of Enhancing Measurement of Personal Life Impact of Rheumatic Diseases. The Journal of Rheumatology. 2011;38(2):191-4.
36. Becede M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49(2):211-7.

37. Melville AR, Kearsley-Fleet L, Buch MH, Hyrich KL. Understanding Refractory Rheumatoid Arthritis: Implications for a Therapeutic Approach. Drugs. 2020;80(9):849-57.
38. Roodenrijs NMT, van der Goes MC, Welsing PMJ, Tekstra J, Lafeber FPJG, Jacobs JWG, et al. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease. Rheumatology. 2020;60(8):3778-88.
39. Watts RA, Conaghan PG, Denton C, Foster HE, Isaacs J, Müller-Ladner U. Oxford Textbook of Rheumatology: Oxford University Press; 2013 2013-10.
40. van der Heijde DM, van 't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis. 1990;49(11):916-20.
41. Smolen JS, Breedveld FC, Schiff MH, Kalden JR, Emery P, Eberl G, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford). 2003;42(2):244-57.
42. Gossec L, Paternotte S, Aanerud GJ, Balanescu A, Boumpas DT, Carmona L, et al. Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Annals of the Rheumatic Diseases. 2011;70(6):935-42.
43. Singh G, Athreya BH, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis and rheumatism. 1994;37(12):1761-9.
44. Boonstra AM, Schiphorst Preuper HR, Balk GA, Stewart RE. Cut-off points for mild, moderate, and severe pain on the visual analogue scale for pain in patients with chronic musculoskeletal pain. Pain. 2014;155(12):2545-50.
45. EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208.
46. Nicklin J, Cramp F, Kirwan J, Greenwood R, Urban M, Hewlett S. Measuring fatigue in rheumatoid arthritis: A cross-sectional study to evaluate the Bristol Rheumatoid Arthritis Fatigue Multi-Dimensional questionnaire, visual analog scales, and numerical rating scales. Arthritis Care & Research. 2010;62(11):1559-68.
47. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford). 2006;45(7):885-9.
48. Mundt JC, Marks IM, Shear MK, Greist JM. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. The British Journal of Psychiatry. 2002;180(5):461-4.
49. Silke L, Kirresh O, Sturt J, Lempp H. Development of the Rheumatoid Arthritis Distress Scale (RADS) – A New Tool to Identify Disease-Specific Distress in Patients with Rheumatoid Arthritis. 2021;5(51):1-21.

Table 1: Characteristics of Delphi Voters (n=106)

	Face-to-Face Nominal Group (N = 13)	Online Delphi Round One (N = 40)	Online Delphi Round Two (N = 53)
Role, n (%)†			
Rheumatologist	5 (38.5%)	11 (27.5%)	17 (32.1%)
Nurse	1 (7.7%)	4 (10%)	3 (5.7%)
GP	1 (7.7%)	3 (7.5%)	3 (5.7%)
Pharmacist	0	1 (2.5%)	3 (5.7%)
Psychologist	0	2 (5%)	3 (5.7%)
Podiatrist	0	1 (2.5%)	1 (1.9%)
Physiotherapist	0	3 (7.5%)	5 (9.4%)
Occupational Therapist	0	2 (5%)	4 (7.6%)
Patient Representatives	3 (23.1%)	8 (20%)	10 (18.9%)
Researcher*	3 (23.1%)	4 (10%)	3 (5.7%)
Social Worker	0	1 (2.5%)	1 (1.9%)
Number of years' experience in Rheumatology, mean (SD)			
Professionals	15.10 (12.07)	15.59 (11.30)	16.07 (8.62)
Patients	21.33 (16.29)	25.62 (14.17)	28 (12.29)
Predominantly trained/worked‡, n (%)			
Adult	9 (90%)	20 (62.5%)	29 (67.4%)
Paediatric	1 (10%)	6 (18.75%)	7 (16.3%)
Both	0	6 (18.75%)	7 (16.3%)
Received specific MSK training‡, n (%)			
Yes	6 (60%)	24 (75%)	32 (76.7%)
No	4 (40%)	8 (25%)	10 (23.3%)

†Although participants were allowed to select multiple roles, the main role is reported here. ‡Professional roles only were reported. *Researchers covered the following disciplines: Radiology, Psychology, Medical Sociology, Rheumatology and Health Services, Statistics and Epidemiology.

Table 2: Revised consensus definition of Refractory Inflammatory Arthritis

	REFRACTORY INFLAMMATORY ARTHRITIS
Part 1: Treatment	DESPITE following Treat-to-Target Strategy using ≥1 csDMARDs, and ≥1 anti-TNF, bDMARDs and/or tsDMARDs with different mechanisms of action
Part 2: Inflammation	Synovial inflammation is PRESENT (Persistent Inflammation) or ABSENT (Persistent Symptoms) as determined by inflammatory markers, physical examination and imaging or composite disease activity
Part 3: Symptoms and Impact	PLUS ≥1 of the following: 1. <u>Disease Activity</u> a. Persistently high inflammation and/or symptoms e.g. with or without fluctuations for at least two consecutive clinical visits over the period of at least six months b. Disease Activity not captured by DAS28 (hands, shoulders, wrists, elbows and knees) including involvement of other joints (hips, temporomandibular, feet), extra-articular manifestations or other inflammatory features (vasculitis, uveitis, tendonitis or enthesitis) or non-inflammatory features (muscle weakness or cachexia) c. Repeated need of short course steroid tablets or intra-articular injections due to inflammatory arthritis manifestations, that may or may not control flare and localised swelling 2. <u>Joint Involvement</u> a. Joint stiffness during the day (longer than 30-60 minutes upon wakening) b. One or two persistently active/affected joints despite acceptable control in other joints c. Accrued damage due to inflammation - Joint erosion(s), deformity(ies) or restrictions in range of movement 3. <u>Pain</u> a. Pain in joints e.g. hands and feet b. Pain during the day and/or night c. Pain Interference impacting on quality of life 4. <u>Fatigue</u> a. Lack of physical energy resulting in difficulties conducting daily activities e.g. washing, dressing b. Lack of mental energy leading to difficulties with concentration and memory 5. <u>Functioning and Quality of Life</u> a. Problems with self-care e.g. washing/dressing b. Inability to perform desired activities e.g. hobbies, social, work c. Poor physical function e.g. lack of strength, dexterity, grip d. Reduced mobility and/or Problems walking, standing, or climbing stairs e.g. driving, use of public transport, needing to sit e. Disease-related distress e.g. psychological distress related to burden of disease including Physical related, Emotional, Social, Treatment or Healthcare Distress 6. <u>cs/b/tsDMARD Experiences</u> a. Primary inefficacy (no response to DMARD at all) and/or Secondary inefficacy (developed DMARD resistance over time) b. Experience of multiple occurrences of inefficacy, intolerability, or discontinuation

Table 3: Assessments mapped onto Refractory Inflammatory Arthritis definition

RIA Definition	Assessment Methods (including cut-offs)
Part 1: Treatment	Treatment History (≥1 csDMARDs, and ≥1 anti-TNF/b/tsDMARDs) (39)
Part 2: Inflammation	Abnormal/Raised Inflammatory markers (ESR / CRP based on the local laboratory standards) (39) Physical examination (TJC/SJC) (39) Imaging (Any) (39)
Part 3: Symptoms and Impact 1. Disease Activity	Clinical Notes / Consultation / Medical and Treatment History (39) DAS28 >3.2 (40) or SDAI >11 (41) RAID (scoring higher on Q5) (42)
2. Joint Involvement	(C)HAQ (Symptoms Section) (26, 43) MSK-HQ (scoring 0-2 on Q1 and/or 2) (25) Consultation / Joint Examination / Clinical Notes (39)
3. Pain	MSK-HQ (scoring 0-2 on Q1 and/or 2) (25) VAS >3.5 (44) EQ5D (scoring 2 or 3 on Q4) (45) RAID (scoring higher on Q1) (42)
4. Fatigue	BRAF (Higher total score and on items) (46) VAS >2.0 (47) General Fatigue MSK-HQ (scoring 0-2 on Q10) (25) RAID (scoring higher on Q3) (42)
5. Functioning and Quality of Life	(C)HAQ ≥1.5 (26, 43) EQ5D (scoring 2 or 3 on Q1-3 and Q5) (45) WSAS (higher total score and on items 1-4) (48) MSK-HQ (scoring 0-2 on Q3-7 and Q11) (25) RAID (scoring higher on Q2 and Q6) (42) RADS (49) Consultation (39)
6. cs/b/tsDMARD Experiences	Clinical Notes / Treatment and DAS28 History / Consultation (39)

Please note: DAS28: Disease Activity Score 28 joint count, SDAI: Simplified Disease Activity Index, RAID: Rheumatoid Arthritis Impact of Disease, (C)HAQ: Child or Adult Health Assessment

Questionnaire, MSK-HQ: Musculoskeletal Health Questionnaire, VAS: Visual Analogue Scale, EQ5D: EuroQol 5-Dimensions, BRAF: Bristol RA Fatigue Scale, WSAS: Work and Social Adjustment Scale, RADS: Rheumatoid Arthritis Distress Scale.


Patient Interviews
HCP Interviews / Focus Groups
Application of Biopsychosocial Theory
Systematic Review of Definitions
Generation of initial components and domains for the definition by study team
Generation of components for the model by study team
Delphi Nominal Group
Initial discussion sense-checking identified components due to multi-disciplinary rheumatology expertise on refractory disease
Voting on name preferences with further suggestions
Voting on inclusion and relatedness of proposed domains
Presentation of Model and Components to KCL Health Psychology Group
Model sense-checking and component feedback due to expertise on model and questionnaire development
Further refinement to produce final components and domains for online Delphi definition voting by study team
Online Voting
Voting on name preferences
Voting on the inclusion of domains
Voting on the relatedness of components
Clarify wording and free text suggestions
Voting from wider international group to include broader experiences and knowledge
Analysis of ratings whether domains/components are included, modified or excluded with re-voting as appropriate
Final refinement, analysis and generation of new definition and model by study team
Phase One
Phase Two


Round One Domains Inclusion
Inclusion Reference Line ≥70%
Include scores rated between 7-9
100%
80%
60%
40%
20%
0%
Disease Activity (n=39)
Stiffness (n=39)
Joint Activity (n=38)
Pain (n=39)
Fatigue (n=39)
Function/QoL - PPS (n=37)
DMARD Experiences (n=37)
Co-morbidities (n=38)
Sleep (n=39)
Healthcare/Medication (n=38)
Domains


Round Two Components Inclusion
Inclusion Reference Line ≥ 70%
Include scores rated between 7-9
100%
80%
60%
40%
20%
0%
Comorbid4
HCMed2
Comorbid1
Comorbid2
Sleep2
HCMed1
Exclusion3
Exclusion1
Comorbid3
HCMed3
Exclusion2
Exclusion4
Sleep1
Components


Predisposing Factors
Biological
Unknown/Idiopathic
Genetics
Hormones / Gender
Long disease duration or disease onset pre-biologics
Physical Triggers e.g. Trauma, Infection, Illness
Psychological
Psychological Triggers that initiate an inflammatory immune response e.g. Physical or Emotional Stressors
Social
Social Triggers that initiate an inflammatory immune response e.g. Environmental or Bereavement
Poor Prognostic Factors
Biological
Radiographic damage, replacement(s) and/or fusion(s)
High levels of symptoms at onset/diagnosis
Delay in treatment or inadequate escalation
Negative Lifestyle Factors e.g. Smoking
RF/anti-CCP positivity
Psychological
History of mental health/pain conditions prior to diagnosis
Early life experiences and family health beliefs
e.g. childhood infections and family response to illness
Social
Lower socioeconomic status
Health inequities including issues in service provision/funding
Perpetuating Factors
Biological
Poor quality sleep
Co-morbidities and other impairments e.g. Osteoarthritis
Mismatch clinician vs patient perception of disease control
Steroid Dependency
Psychological
Low resilience/self-esteem/confidence
Adjustment and Acceptance Difficulties
Maladaptive coping or self-management strategies
Negative treatment beliefs and poor adherence
Social
Reduced independence/autonomy
Isolation, loneliness and relationship difficulties
Other life stresses e.g. caring for others
REFRACTORY INFLAMMATORY ARTHRITIS
DESPITE using ≥1 csDMARDs, and ≥1 anti-TNF, bDMARDs and/or tsDMARDs
PERSISTENT SYMPTOMS
PERSISTENT INFLAMMATION
SYMPTOMS AND IMPACT
Protective Factors
Biological
Positive Lifestyle Factors e.g. non-smoker,
Maintenance of good physical function
Good availability/access and use of MDT care
Psychological
Effective Self-Management and Active Coping Strategies
Positive treatment and Illness beliefs
Resilience/Patient Activation/Self-efficacy
Successful Adjustment and Acceptance
Social
Good social support/network
Maintenance of independence
Ability to continue desired activities, hobbies and work
Potential Management Strategies
Biological
Refractory Inflammatory Arthritis Clinic or Longer Consultation/Annual Review
Additional tests to exclude treatable co-morbidities
Multi-Disciplinary support internal to Rheumatology and external referrals
Optimise current or change drug management (FOR PI ONLY)
Surgery Referral if appropriate for joint replacements/fusions (FOR PI ONLY)
Further imaging to determine any subclinical inflammation (FOR PS ONLY)
Psychological
Supported Self-Management and Patient (Re-)Education programmes on disease processes, joint education and management, including additional active coping strategies
Social
Signposting to online and local support groups and patient organisations